Inovio axes staff, chops R&D programs in chase for elusive commercial win — though there's still a lot on their plate
Rallying around its late-stage HPV projects, Inovio Pharmaceuticals $INO is slashing 28% of its workforce — around 80 staffers — and axing several early-stage programs to bring …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
